Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5705_Библиотеки_им_академика_М_И_Перельмана.pdf
28
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
Cosmetic Applications. Eur. J. Pharm. Biopharm. 2019, 144, 18–39.
Int. J.
Nanomed. 2012, 7, 1139–1148.
Eur. J.
Pharm. Sci. 2017, 99, 240–245.
Nanobiomedicine
2018, 5, 1–11.
poly (Butyl cyanoacrylate) Nanoparticles. Int. J. Pharm. 2012, 426, 193–201.
Abary
Salah, M. Natamycin Niosomes as a Promising Ocular
In vitroIn vivo and Histopathological Studies. Drug Dev. Ind.
Pham. 2019, 45, 922–936.
Drug Dev. Ind. Pharm. 2020,
46, 806–813.
Sci. Rep. 2016, 6,
1–12.
Zhongguo Zhongyao Zazhi 2010, 35, 1560–1565.
Expert Rev. Vaccines 2003, 2, 253–267.
in vitro
Doxyxycline Hyclate Niosome as a Potential Ocular Delivery System. Int. J. Pharm. 2019,
567,
11843
Pharmaceutics 2022, 14, 1147.
J. Control.
Release 2009, 133, 96–102.
Preparation and Cellular Uptake In Vitro. Pharmazie. 2005, 60, 473–474.
Ann. Dunarea Jos Univ. Galati Fascicle XII Weld. Equip. Technol.
2008, 32, 9–16.
Int. J. Appl. Pharm. 2017, 9, 38–43.
Niosomes in Delivery of Therapeutics and Biomedical Application
29
Int. J. Nanomed. 2013, 8,
421–430.
Int. J.
Pharm. 2012, 423, 303–311.
J. Drug Deliv. Ther.
2018, 8, 35–43.
Delivery System. J. Drug Deliv. Ther. 2021, 11, 162–170.
J.
Liposome Res. 2020, 30, 163–173.
Int. Immunopharmacol. 2004, 4, 279–287.
Glycoside Vesicles as Drug Carriers. I. Preparation and Physical Properties. Chem. Pharm.
Bull. 1985, 33, 753–759.
Colloids
Surf. B 2022, 211, 112–298.
DTPA Niosomes in Diagnostic
Imaging. 2000; pp 227–242.
Acta Pharm. Sin. B. 2011, 1, 208–219.
Asian J. Pharm. 2012, 7, 96–109.
Phytomedicine
2007, 14, 778–784.
Drug
Deliv. 2013, 20, 277–284.
Molecules
2022, 27, 1372.
and In Vivo Studies. AAPS Pharm. Sci. Tech. 2021, 22, 58.
2
Physicochem. Eng. Asp. 2007, 293,
255–261.
Liver Cancer. Int. J. Nanomed. 2014, 10, 257–270.
30
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
Radiology 2004, 231,
135–142.
Molecules 2018, 23,
1756.
Int. J. Res. Pharm.
2011, 1, 498–511.
Adv. Colloid
Interface Sci. 2012, 183–184, 46–54.
Eur. J. Pharm. Sci. 2013, 48, 474–483.
Compounds. Pharm. Biol. 2012, 50, 208–224.
J. Microencapsul. 2010, 27, 272–280.
J. Control Release 2010, 147, 127–135.
In Vivo. Methods Mol. Biol. 2011, 751, 145–165.
Vivo. Bioconjug. Chem. 2008, 19, 983–987.
Colloids Surf. A Physicochem. Eng.
Asp. 2014, 442, 69–79.
Pharmaceutics 2021, 13
(3), 394.
Polycations Bearing Quaternary Ammonium Moieties. Int. J. Mol. Sci. 2017, 18, 1139.
Doxorubicin-containing PEG Liposome. Eur. J. Pharm. Biopharm. 2021, 169, 20–28.
Cells. Mol. Pharm. 2011, 8, 852–866.
J. Microencapsul. 2010, 27, 618–627.
Niosomes in Delivery of Therapeutics and Biomedical Application
31
J. Control. Release 2014, 185, 22–36.
Pharmaceutics 2021, 13, 59.
Pharmaceutics 2021,
13 (1), 59.
. J. Appl. Pharm. Sci. 2011, 1, 20–23.
Eur. J. Pharm. Sci.
1999, 8, 177–185.
Hydrophobic Anticancer Drugs Using Biocompatible pH-sensitive Lipid-based Nano-
RSCAdv. 2017, 7, 30008–30019.
Pharm. Times 2009, 41, 11–14.
Responses. J. Liposome Res. 2021, 31, 195–202.
Responses. J. Liposome Res. 2021, 31 (2), 195–202.
AAPS
PharmSciTech. 2017, 19, 481–488.
J. Pharm. Pharmacol. 2013, 65,
1158–1167.
Containing Resveratrol. J. Food Eng. 2013, 117, 227–234.
Colloids Surf. B 2015, 128, 398–404.
JPSBR. 2012, 2,
169–175.
P-glycoprotein Expression, Multidrug Resistance-associated Protein (MRP1) Expression,
J. Pharmacol. Sci.
2001, 90, 1829–1837.
Ther.
Deliv. 2018, 9, 343–357.
32
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
Delivery System. Biol. Pharm. Bull. 2011, 34, 945–953.
J. Appl.
Pharm. Sci. 2011, 8, 12–20.
Curr. Drug
Discov. Technol. 2013, 10, 270–282.
Anti-oxidant Coated Liposome
as the Delivery System for Papain Based Natural Cosmetics.
Enabling Science and Nanotechnology (ESciNano): Malaysia, 2010, pp 1–1.
AAPS
Pharm. Sci. Tech. 2010, 11, 1119–1127.
Niosomes on Chemically Induced Hepatocellular Carcinoma in Rats. J. Drug Deliv. Sci.
Technol. 2021, 61, 102–163.
Int. J.
Nanomed. 2019, 14, 9777–9792.
Enhancement: In Vitro and In Vivo Assessment. Pharmaceutics 2021, 13, 138.
Pharmacologyonline 2009,
2, 926–932.
Int. J. Pharm.
2013, 440, 179–187.
Clin. Chim.
Acta. 2004, 348, 63–68.
Glioma. Int. J. Mol. Sci. 2021, 22, 45–56.
. Int. J. Mol. Sci. 2019, 20, 46–96.
RSC Adv.
2017, 7, 33378–33384.
Carriers: Fundamentals and Recent Applications. J. Nanomater. 2016.
Drug. AAPS PharmSciTech. 2015, 16, 108–117.
Niosomes in Delivery of Therapeutics and Biomedical Application
33
Evaluation. J. Drug Deliv. Sci. Technol. 2020, 59, 101863.
Int. J. Mol. Sci. 2021,
22, 15–35.
Nimesulide. J Pharm. Pharm. Sci. 2002, 5, 220–225.
17-Hydroxyprogesterone Caproate. J. Drug Deliv. Sci. Technol. 2021, 61, 102215.
Mater. Sci. Eng. C. 2015, 56, 393–400.
Acid on Melanogenesis Inhibition. Int. J. Cosmet. Sci. 2000, 22, 291–303.
Doxorubixin Selected K562 Human Leukemia Cells. Int. J. Oncol. 2000, 17, 387–479.
J. Drug Deliv. Sci.
Technol. 2020, 58, 101791.
. Eur. J. Pharm. Biopharm. 2011, 79,
189–196.
’Nat.
Rev. Cancer. 2008, 8, 473–480.
Fractions in Blood and Brain. J. Pharmacol. Exp. Ther. 2006, 316, 1282–1290.
Int. J. Mol. Sci. 2021, 22, 5698.
Langmuir
2013, 29, 12638–12646.
Drug Delivery. Drug Dev. Ind. Pharm. 2020, 46, 751–761.
Methods 2022, 199, 9–15.
Pharmaceutical Chemistry. Adv. Colloid Interface Sci. 1995, 58, 1–55.
Int. J. Pharm. 1998, 172, 33–70.
34
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
Progesterone. J. Biol. Chem. 1992, 267, 24248–24252.
Gene Delivery. RSC Adv. 2018, 8, 31934–31942.
Int. J. Pharm. 2013, 456, 446–458.
against breast cancer. Tumor Biol. 2016, 37, 12301–12313.
J. Physiol.
Biochem. 2017, 73, 157–165.
ACS Appl. Mater. Interfaces 2018, 10, 19494–19503.
Cancer In Vitro and In Vivo. Sci. Rep. 2015, 5, 1–15.
Int. J. Pharm. 2022, 624, 121878.
Sci. Rep. 2016, 6, 20051.
J. Biomater. Sci. Polym. Ed. 2021, 32, 858–873.
Int. J. Pharm. 2020, 580, 119–183.
Sci. Rep. 2016, 6, 1–12.
Int. Immunopharm. 2017, 42, 32–38.
Ulcerative Colitis Rats. Artif. Cells Nanomed. Biotechnol. 2018, 46, 324–335.
Advances in Pharmaceutical T echnology for Drug Delivery Systems (PTDDS), Volume 2: Recent Progress
in Biomedical Applications. Sougata Jana (Ed.)
© 2025 Apple Academic Press, Inc. Co-published with CRC Press (Taylor & Francis)
Advances for Medical Applications in
Breast Cancer and Cardiotoxicity
LUÍSA MEDEIROS CARSTEN
1
, JOANA RIBEIRO COLOMBO BARBISAN
1
,
KAIUSMUNHOZ DE PAULA
1
, ÉRICA GABRIELI DOS SANTOS DA SILVA
2
,
TALITA DE OLIVEIRA FELIPPE
1
, JULIANO LUIZ DE LIMA
1
,
TARSO WALTRICK
1
, MICHAEL RAMOS NUNES
2
,
CLEONICE GONÇALVES DA ROSA
1
, and NATALIA VERONEZ DA CUNHA
1
1
2
CHAPTER 2
ABSTRACT
-
addition to physical activity, both cancer and the cardiotoxicity caused by
chemotherapy drugs can be modulated by healthy and balanced diets and
nutritional therapies, based on antioxidant supplements. As an alternative,
-
nology and biomedicine as an unprecedented technological revolution and
-
breast cancer.
36
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
2.1 INTRODUCTION
Boer et al., 2017). Sedentary habits and unbalanced diets lead to an increased
physically inactive (de Boer et al., 2017).
al., 2021). Some mechanisms that explain this relationship are the procar-
-
sion, increased estrogen in obese patients, nicotine in smokers, and tumor
instance, depending on the drug used, the risk may vary according to the
cancer but can increase mortality risk due to other conditions such as cardio-
vascular diseases (Kerr et al., 2022).
-
Advances for Medical Applications in Breast Cancer and Cardiotoxicity
37
in the thoracic region. Systemic high blood pressure and thromboembolism
treating these individuals are crucial to prevent and treat such adverse
-
oncological rehabilitation period, physical activity is considered the main
element, but not yet as a standard model to treat and control cardiovascular
-
oxidative stress caused by chemotherapy (Ortega et al., 2021), in addition to
hormones (de Boer et al., 2017).
prevent cardiovascular toxicity induced by chemotherapy drugs in patients
but little is mentioned about exercises practiced during cancer treatment.
in reducing cardiotoxicity, especially the one caused by anthracyclines.